Feed Items
- previous post: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial
- next post: Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation
